How should tirzepatide be prescribed for alcohol use disorder?

Tirzepatide Should NOT Be Prescribed for Alcohol Use Disorder

Tirzepatide is not an established or guideline-recommended treatment for alcohol use disorder and should not be prescribed for this indication. The medication lacks FDA approval for AUD, has no supporting clinical practice guidelines, and the available evidence consists only of preliminary case reports and animal studies published in 2023-2026—far too recent and limited to justify clinical use.

Established Pharmacotherapy for Alcohol Use Disorder

Based on current guidelines, the appropriate medications for AUD are 1:

FDA-Approved Options:

• Acamprosate: 666 mg three times daily (1,998 mg/day for patients ≥60 kg; reduce by one-third for <60 kg). No hepatic metabolism, making it the safest option in liver disease 1, 2
• Naltrexone: 50 mg/day orally or 380 mg monthly subcutaneous. Contraindicated in alcohol-associated liver disease due to hepatotoxicity risk 1, 2
• Disulfiram: Not recommended in ALD due to hepatotoxicity 1, 3

Non-FDA Approved but Evidence-Based:

• Baclofen: 30-60 mg/day (typically 10 mg three times daily). This is the ONLY medication with RCT evidence specifically in patients with cirrhosis and ALD 1. Avoid in hepatic encephalopathy as it may worsen mental status
• Gabapentin: 600-1,800 mg/day. Monitor for renal dysfunction and sedation 1
• Topiramate: 75-400 mg/day 1

Why Tirzepatide Is Not Appropriate

The evidence for tirzepatide consists of:

• Three case reports showing reduced alcohol intake 4
• Retrospective observational data 5
• Animal studies 6, 7
• Social media analysis 8

Critical limitations:

• No randomized controlled trials in humans with AUD
• No established dosing protocols for AUD
• Unknown safety profile for this indication
• One case report of Korsakoff syndrome developing during tirzepatide therapy in a patient with chronic alcohol use 9
• The drug label information provided 10 appears to be for a homeopathic product, not the FDA-approved GLP-1/GIP agonist

Recommended Treatment Algorithm

For patients WITHOUT liver disease:

1. First-line: Naltrexone 50 mg/day OR Acamprosate 666 mg three times daily
2. Combine with cognitive behavioral therapy or motivational enhancement therapy 1
3. Consider gabapentin or topiramate if first-line agents fail

For patients WITH alcohol-associated liver disease:

1. First-line: Baclofen 10 mg three times daily (only medication with RCT evidence in cirrhosis) 1
2. Alternative: Acamprosate (no hepatotoxicity, renally excreted) 1, 2
3. Avoid naltrexone and disulfiram due to hepatotoxicity 1, 2, 3, 2
4. Exclude patients with hepatic encephalopathy from baclofen therapy

All patients require:

• Integration of pharmacotherapy with psychosocial interventions 1
• Treatment duration: minimum 3-6 months, up to 12 months 2
• Thiamine supplementation (100-300 mg/day) to prevent Wernicke-Korsakoff syndrome 2

Common Pitfalls

• Prescribing naltrexone in patients with elevated liver enzymes or known liver disease
• Using medications without concurrent behavioral therapy—combination is essential 1, 11
• Failing to provide thiamine supplementation, especially during alcohol withdrawal 2
• Attempting novel off-label therapies like tirzepatide when evidence-based options exist

The emerging data on GLP-1/GIP agonists and alcohol consumption is intriguing but premature for clinical application. Stick with guideline-recommended therapies that have established efficacy and safety profiles.